- Trials with a EudraCT protocol (195)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
195 result(s) found for: Reproductive loss.
Displaying page 1 of 10.
EudraCT Number: 2016-004981-24 | Sponsor Protocol Number: Plaquenil | Start Date*: 2017-04-12 | |||||||||||
Sponsor Name:Henriette Svarre Nielsen | |||||||||||||
Full Title: Hydroxychloroquin (Plaquenil) treatment of recurrent pregnancy loss – a randomized, double blinded, placebo controlled study | |||||||||||||
Medical condition: Recurrent pregnancy losses. Women with >3 subsequent pregnancy losses or 3 pregnancy losses of which one was a 2. trimester loss. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000084-40 | Sponsor Protocol Number: NT-05 | Start Date*: 2014-04-07 | |||||||||||
Sponsor Name:Nora Therapeutics, Inc. | |||||||||||||
Full Title: A randomized, double blind, multi-center, placebo-controlled study to evaluate the efficacy, safety, and tolerability of NT100 in pregnant women with a history of unexplained recurrent pregnancy lo... | |||||||||||||
Medical condition: Unexplained recurrent pregnancy loss. A distinct disorder from sporadic pregnancy loss and is characterized by the loss of multiple pregnancies | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000066-37 | Sponsor Protocol Number: NM-V-101 | Start Date*: 2013-01-16 | |||||||||||
Sponsor Name:Nordmark Arzneimittel GmbH & Co. KG | |||||||||||||
Full Title: Double-blind, randomized, placebo-controlled study on efficacy, safety and tolerability of ancrod in patients with sudden sensorineural hearing loss | |||||||||||||
Medical condition: sudden sensorineural hearing loss (SSHL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000256-35 | Sponsor Protocol Number: CNPOBC2020 | Start Date*: 2020-12-16 | |||||||||||
Sponsor Name:Aalborg University Hospital | |||||||||||||
Full Title: Intravenous immunoglobulin and prednisolone to women with unexplained recurrent pregnancy loss after assisted reproductive technology treatment: a randomised, double-blind, placebo-controlled trial | |||||||||||||
Medical condition: Recurrent pregnancy loss after assisted reproductive technology treatment | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006220-40 | Sponsor Protocol Number: 2022-0101-01 | Start Date*: 2022-06-30 | ||||||||||||||||||||||||||
Sponsor Name:Hvidovre Hospital, Department of Gynecology | ||||||||||||||||||||||||||||
Full Title: Double-blinded randomized placebo-controlled trial on tacrolimus in women with an euploid pregnancy loss and PCOS and/or thyroid autoimmunity | ||||||||||||||||||||||||||||
Medical condition: Polycystic ovarian syndrome and/or thyroid autoimmunity in combination with an euploid pregnancy loss | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||||||||||||
Trial protocol: DK (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005419-18 | Sponsor Protocol Number: 01INMUNOGEST14 | Start Date*: 2016-07-01 | |||||||||||
Sponsor Name:silvia sanchez ramon | |||||||||||||
Full Title: CLINICAL TRIAL, PHASE III, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED WITH INTRAVENOUS IMMUNOGLOBULIN HUMAN FOR THE TREATMENT OF REPEAT ABORTION WITH IMMUNE ETIOLOGY | |||||||||||||
Medical condition: recurrent aborption with inmunological etiology | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002757-72 | Sponsor Protocol Number: NEOSH101-CLIN-AGA003 | Start Date*: 2006-11-30 | |||||||||||
Sponsor Name:Neosil Inc. | |||||||||||||
Full Title: A Phase 2 Multicenter, Randomized, Placebo- and Comparator Controlled, Double-Blind Parallel Group Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alo... | |||||||||||||
Medical condition: The study will be performed in male subjects with androgenetic alopecia, Norwood -Hamilton grades III - IV. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-000511-28 | Sponsor Protocol Number: NEOSH101-CLIN-AGA004 | Start Date*: 2007-04-20 | |||||||||||
Sponsor Name:Neosil Inc. | |||||||||||||
Full Title: A Phase 2 Multicenter, Randomized, Placebo-Controlled, Double-Blind Parallel Group Dose-Ranging Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alopec... | |||||||||||||
Medical condition: The study will be performed in male subjects with androgenetic alopecia, Norwood-Hamilton grades III - IV. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004439-22 | Sponsor Protocol Number: CHUBX2018/64 | Start Date*: 2020-03-12 | ||||||||||||||||
Sponsor Name:CHU de Bordeaux | ||||||||||||||||||
Full Title: TRAnexamic Acid for Preventing blood loss following a cesarean delivery in women with placenta pREVIA: a multicenter randomised, double blind placebo controlled trial (TRAAPrevia) | ||||||||||||||||||
Medical condition: Postpartum hemorrhage, placenta previa, prevention, blood loss, transfusion | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: FR (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003561-26 | Sponsor Protocol Number: BAY1002670/15790 | Start Date*: 2017-12-14 | |||||||||||||||||||||
Sponsor Name:Bayer AG | |||||||||||||||||||||||
Full Title: A randomized, parallel-group, double-blind and placebo-controlled, multicenter study to assess the efficacy and safety of vilaprisan in subjects with uterine fibroids | |||||||||||||||||||||||
Medical condition: Leiomyoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-004269-14 | Sponsor Protocol Number: BIRD2018001 | Start Date*: 2019-11-08 |
Sponsor Name:Belgian IBD research and development | ||
Full Title: Loss of RESponse to Ustekinumab treated by dose Escalation | ||
Medical condition: Crohn’s disease | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2009-016921-32 | Sponsor Protocol Number: HSJD-OB-TRP | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Fundació Sant Joan de Déu | |||||||||||||
Full Title: A phase II, randomized, double-blind, placebo-controlled, in parallel groups clinical trial to assess the safety and efficacy of dietary supplementation with tryptophan to achieve weight loss, and ... | |||||||||||||
Medical condition: obesity | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003016-87 | Sponsor Protocol Number: C3651003 | Start Date*: 2023-03-13 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PONSEGROMAB IN PATIENTS WITH CANCER, CACHEXIA, AND ELEVATED CONCENTRATIONS OF G... | |||||||||||||
Medical condition: Cachexia, a loss of weight due to the catabolism of muscle and fat tissue. The progressive worsening of cachexia impacts a cancer patient’s quality of life and contributes to poor survival. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Trial now transitioned) HU (Completed) BG (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004956-23 | Sponsor Protocol Number: IIBSP-DIU-2015-85 | Start Date*: 2016-02-25 |
Sponsor Name:Institut de Recerca HSCSP | ||
Full Title: COLIBRI STUDY, Cooper and Levonorgestrel Intrauterine Device (IUD) Barcelona Research Initiative. A randomized controlled trial to compare the menstrual bleeding profile among cooper and 13,5mg lev... | ||
Medical condition: Contraception | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000689-13 | Sponsor Protocol Number: HRT1vs2week.2018 | Start Date*: 2018-07-11 | |||||||||||
Sponsor Name:University hospital Brussel | |||||||||||||
Full Title: Clinical pregnancy rate for frozen embryo transfer with HRT: a pilot study comparing 1 versus 2 weeks of treatment | |||||||||||||
Medical condition: Subfertility in need of IVF and IVF-ICSI treatment | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001539-29 | Sponsor Protocol Number: alsbjerg1 | Start Date*: 2019-10-11 | |||||||||||
Sponsor Name:The Fertility Clinic, Skive Regional Hospital | |||||||||||||
Full Title: Optimizing serum progesterone level during luteal phase in hormone replacement therapy frozen embryo transfer (HRT-FET) cycle – interventional and observational trial | |||||||||||||
Medical condition: Infertility | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001144-36 | Sponsor Protocol Number: CHUBX2015/41 | Start Date*: 2017-11-23 | ||||||||||||||||
Sponsor Name:CHU de Bordeaux | ||||||||||||||||||
Full Title: TRAnexamic Acid for Preventing postpartum hemorrhage following a Cesarean Delivery :a multicenter randomised, double blind placebo controlled trial (TRAAP2) | ||||||||||||||||||
Medical condition: Postpartum hemorrhage, prevention, blood loss, transfusion | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-004429-17 | Sponsor Protocol Number: CO39303 | Start Date*: 2018-09-19 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL TESTING IPATASERTIB PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE, RELATIVE TO PLACEBO PLUS ABIRATERONE PLUS PREDNISONE/... | |||||||||||||
Medical condition: Metastatic Castrate-Resistant Prostate Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: NO (Completed) PT (Completed) DE (Completed) DK (Completed) HU (Completed) GB (GB - no longer in EU/EEA) AT (Completed) IE (Completed) BE (Completed) ES (Ongoing) GR (Completed) PL (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003543-30 | Sponsor Protocol Number: EB93 | Start Date*: 2012-08-24 | ||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Emotional Brain BV | ||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A double-blind, randomized, placebo-controlled, proof of concept study to investigate the differences between the combined administration of 0.5 mg sublingual testosterone and 10 mg buspirone and 1... | ||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Hypoactive Sexual Desire Disorder Sexual Interest/Arousal Disorder | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000345-41 | Sponsor Protocol Number: BIRD2020001 | Start Date*: 2021-09-10 |
Sponsor Name:Belgian IBD research and development (BIRD vzw) | ||
Full Title: An Open-Label Extension and long-term efficacy and safety monitoring study of patients with Crohn’s disease previously included in the loss of RESponse to Ustekinumab treated by dose Escalation stu... | ||
Medical condition: Crohn's disease | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Trial now transitioned) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
